GILD
$144.40
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunl...
Recent News
Gilead Sciences Conference: 6-Month HIV Regimens, 12-Month PrEP, Livdelzi Expansion, Oncology Push
Gilead Sciences (NASDAQ:GILD) executives outlined the company’s approach to next-generation HIV medicines, ongoing commercialization efforts in liver disease, and a broad slate of oncology and inflammation programs during a discussion hosted by Leerink Partners analyst Daina Graybosch. HIV: Moving
Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth
Gilead Sciences (NASDAQ:GILD) Chief Financial Officer Andrew Dickinson told investors at the Barclays conference that the company is entering what he described as “the beginning of a long cycle,” supported by recent launches, a broadening pipeline, and continued operating discipline. Dickinson said
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.
2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch
By taking advantage of Barchart’s scanning tools and doing a small bit of legwork, investors can gain powerful insights.
Gilead Sciences, Inc. (GILD): Growth Prospects Backed by Analyst Upgrades
Gilead Sciences Inc. (NASDAQ:GILD) is one of Goldman Sachs top healthcare stocks. On March 10, Jefferies initiated coverage of Gilead Sciences Inc. (NASDAQ:GILD) with a Buy rating and a $180 price target. The research firm has touted the company’s earnings-per-share growth and margin-expansion prospects as part of its bullish thesis. According to the research firm, […]